Analysis of internal exposure of some nuclear medicine staff performing 131I therapy in Hubei province from 2021 to 2023
10.3760/cma.j.cn112271-20240920-00367
- VernacularTitle:2021—2023年湖北省部分 131I治疗工作人员内照射水平分析
- Author:
Gangtao SUN
1
;
Fang WANG
;
Jianfeng ZHANG
;
Li RAN
;
Hezheng ZHAI
;
Liangying MEI
;
Wenshan ZHOU
Author Information
1. 湖北省疾病预防控制中心放射卫生监测与评价部，武汉 430079
- Publication Type:Journal Article
- Keywords:
Nuclear medicine;
131I;
Thyroid;
Internal exposure
- From:
Chinese Journal of Radiological Medicine and Protection
2025;45(6):519-525
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the current status of occupational internal exposure of nuclear medicine staff performing 131I treatment, and explore the related influence factors, so as to provide a basis for protection against internal exposures. Methods:A survey was conducted using cluster random sampling method to ascertain all the nuclear medicine staff involved in 131I treatment in nuclear medicine hospitals in Hubei province for the years 2021 to 2023. The in vitro monitoring mesurement was made of the 131I activity in thyroid by using portable gamma spectrometer, and the committed effective dose was estimated. Results:The positive detection rate of 131I in treatment staff was between 18.75% and 21.12%, with an average of 20.08%. The highest value found in cleaning and nursing staff in iodine therapy workplaces. The detection rate found in two hospitals were up to 75.61% and 64.71%, respectively. The detection rate was positive for the three consecutive years. There was no statistically significant difference in the committed effective dose between different treatment positions, and the level of internal exposure was lower than the external exposure arising from nuclear medicine practice. Factors affecting detection rate of 131I in thyroid included the amount of 131I used for treatment, and disorder type for treatment, 131I dose, use or otherwise of automated radiopharmaceutical dispenser, and ventilation in treatment rooms. Conclusions:Continuous attention should be paid to the internal exposure of nuclear medicine staff for use of 131I for treatment. Ventilation should be provided regularly, as required, to the 131I treatment rooms and active rooms and the staff should wear masks during the relevant working processes.
